Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049511 | 0.90 | MET (1.00) | METKDR | |
| SCHEMBL5094665 | 0.86 | MET (1.00) | METKDR | |
| SCHEMBL5050781 | 0.84 | MET (1.00) | METKDRIGF1R | |
| SCHEMBL14289201 | 0.83 | MET (1.00) | METKDR | |
| SCHEMBL5107654 | 0.81 | MET (1.00) | METKDR | |
| SCHEMBL5049584 | 0.81 | MET (1.00) | METKDR | |
| SCHEMBL5056188 | 0.80 | MET (1.00) | METKDR | |
| SCHEMBL5050783 | 0.80 | MET (1.00) | METKDR | |
| SCHEMBL1893668 | 0.80 | PDGFRA (0.77) | METKDRIGF1R | |
| SCHEMBL5054203 | 0.79 | MET (1.00) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MET 3/4885KDR 11/4885IGF1R 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.